<DOC>
	<DOCNO>NCT02709096</DOCNO>
	<brief_summary>This Phase 2a study conduct healthy volunteer order evaluate comparative reduction Propionibacterium acnes in-vivo follow daily topical administration BPX-01 Minocycline 1 % Topical Gel ( BPX-01 ) BPX-01 Vehicle control .</brief_summary>
	<brief_title>BPX-01 Minocycline 1 % Topical Gel Reduction Propionibacterium Acnes</brief_title>
	<detailed_description>The objective study evaluate comparative reduction Propionibacterium acne ( P. acne ) in-vivo follow daily topical administration BPX-01 Minocycline 1 % Topical Gel BPX-01 Vehicle control Gel . A secondary objective ass tolerance treatment regimen versus vehicle control . Safety laboratory data ( chemistry hematology ) plasma level minocycline also significant interest sponsor . This single center , randomize , double blind , two-cell , vehicle control P. acne study . All subject randomize 2:1 1 % BPX-01 vehicle control apply topical gel daily four ( 4 ) week . This six ( 6 ) week study four ( 4 ) week treatment period two ( 2 ) week post treatment follow visit . The clinical endpoint in-vivo quantification P.acnes . The safety/tolerance endpoint ; observer report : erythema , scaling-peeling , edema , subject report : tightness , burning-stinging , itch . Plasma level minocycline basic hematology chemistry laboratory value collect .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Be healthy , adult male and/or female volunteer 18 40 year age past present history significant disease base PI discretion ; 2 . If female , must postmenopausal , surgically sterile , use effective birth control method negative urine pregnancy test Screening Baseline visit ( female subject childbearing potential ) ; 3 . Show high degree fluorescence face Wood 's lamp screen visit . 4 . Be willing refrain use antimicrobial topical product duration study participation ; 5 . Be willing return study center study visit ; 6 . Be willing follow study instruction adhere study restriction ; 7 . Provide informed consent study procedure restriction 1 . Have history skin disease presence skin condition PI believe would interfere study ; 2 . Females report pregnant , plan pregnancy breastfeed female child bear potential , test positive urine pregnancy test ; 3 . Have condition factor PI believe may affect response skin interpretation result ; 4 . Participated clinical study within previous 30 day , concurrently participate study , involve aspect test administration ; 5 . Use topical systemic antibiotic product within previous 4 week prior baseline , influence P. acnes count ; 6 . Are know allergic test product ( ) components test product ( ) ; 7 . Have history significant medical condition/disease PI believe may affect response skin interpretation result ; 8 . Has condition , opinion Investigator designee , could interfere subject 's ability use treatment instruct , alter treatment response , affect ability complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>